InvestorMind

Revenue up 16% versus 2015. 2016 Fully Diluted EPS was $0.30 as compared to $0.26 in 2015. As at December 31, 2016, the Company had cash, cash equivalents, and short term investments totalling $13,739,286 as compared to $9,715,476 as at December 31, 2015 - a 41% increase. Cash and cash equivalents $13,056,086 vs $4,392,617 - 197% increase. However, this could be deceptive as it looks like cash grew due to sale of short term investments. Shares outstanding is 14,401,087. Cash, cash equivalents, and short term investments totalling $13,739,286 almost equal to number of shares. No debts. Price yesterday closed at $7.35. When earnings was announced this morning, price went up to $8 or 8.84%. Closed at $7.47. Bought at $7.50 using limit order good till cancelled but was filled right away even though ask price was $7.6 to $7.75. It may be irrelevant but should have probably tried limit order at bid price. Volume was high today due to earnings release. Did not really follow the

TORONTO, ONTARIO--(Marketwired - Mar 15, 2017) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2016. Key highlights include: 2016 Net Revenues of $17,922,270 increased by 16% versus 2015  Fourth quarter (Q4) 2016 Net Revenues of $5,009,668 a record quarter for the Company, increased by 30% versus Q4 2015  2016 Pharmaceutical Net Revenues of $16,663,159 increased by 16% versus 2015  Q4 2016 Pharmaceutical Net Revenues of $4,922,773 increased by 30% versus Q4 2015  2016 EBITDA 1  of $5,900,080 increased by 15% versus 2015  Q4 2016 EBITDA 1  of $1,591,047 increased by 58% versus Q4 2015  2016 Net Income After Tax (NIAT) of $4,309,505 increased by 14% versus 2015  2016 NIAT percentage to Net Revenues was 24% as compared to 24% in 2015  Q4 2016 NIAT of $1,094,822 increased by 44% versus Q4 2015  Q4 2016 NIAT percentage to Net Revenues of 22% compares to 20% in Q4 2015  2